Citigroup initiated coverage on ArriVent BioPharma with a new price target
$AVBP
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $30.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2025 | $45.00 | Buy | BTIG Research |
| 11/25/2025 | $43.00 | Buy | Truist |
| 7/10/2025 | $33.00 | Buy | Goldman |
| 3/20/2025 | $37.00 | Buy | B. Riley Securities |
| 3/10/2025 | $45.00 | Buy | Guggenheim |
| 7/22/2024 | $35.00 | Outperform | Oppenheimer |
| 4/30/2024 | $25.00 | Buy | H.C. Wainwright |
| 2/20/2024 | $35.00 | Buy | Jefferies |
4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
4 - ArriVent BioPharma, Inc. (0001868279) (Issuer)
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination strategies[1], with the FDA fast-tracking multiple targeted therapies designed to transform immunologically cold tumors into treatment-responsive hot targets[2]. This pivotal shift positions Oncolytics Biotech Inc. (NASDAQ:ONCY), AIM ImmunoTech (NYSE-American: AIM), ArriVent BioPharma, Inc. (NASDAQ:AVBP), Merus N.V. (NASDAQ:MRUS), and Halozyme Therapeutics, Inc. (NASDAQ:HALO) as potential leaders in the battle against stolid tumors, including gastrointestinal ca
Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in ChinaEstablised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial OfficerCash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027 NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("Company" or "ArriVent") (Nasdaq: "AVBP"), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h
SCHEDULE 13G/A - ArriVent BioPharma, Inc. (0001868279) (Subject)
10-Q - ArriVent BioPharma, Inc. (0001868279) (Filer)
8-K - ArriVent BioPharma, Inc. (0001868279) (Filer)
BTIG Research initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $45.00
Truist initiated coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $43.00
Goldman resumed coverage of ArriVent BioPharma with a rating of Buy and set a new price target of $33.00
Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with ongoing Phase 1 study in ChinaEstablised commercial leadership within excutive team with appointment of Brent S. Rice as Chief Commercial OfficerCash and investments of $305.4 million as of September 30, 2025 expected to fund operations into mid-2027 NEWTOWN SQUARE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("Company" or "ArriVent") (Nasdaq: "AVBP"), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical
NEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent with over 25 years of U.S. and global commercial experience in the biotechnology and pharmaceutical industry. "Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning," said Bing Yao, Chairman and Chief Executive Officer of ArriVent. "We are excited to welcome h
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results
SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)
SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)
SC 13G - ArriVent BioPharma, Inc. (0001868279) (Subject)